Is Doximity A Good Long-Term Stock?
For questions about this article or underlying research, email help@trefis.com. Doximity (DOCS) stock has lost 36.8% over the past year, against a 12.8% gain for the S&P 500. Whether to keep holding depends on whether Doximity’s pharma ad business keeps producing the cash for its buyback. Over three years, the company has cut its diluted […]